𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Application of a Physiologically Based Pharmacokinetic Model Informed by a Top-Down Approach for the Prediction of Pharmacokinetics in Chronic Kidney Disease Patients

✍ Scribed by Sayama, Hiroyuki; Takubo, Hiroaki; Komura, Hiroshi; Kogayu, Motohiro; Iwaki, Masahiro

Book ID
125405848
Publisher
American Association of Pharmaceutical Scientists
Year
2014
Tongue
English
Weight
921 KB
Volume
16
Category
Article
ISSN
1550-7416

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prediction of the disposition of midazol
Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model
✍ Sven Björkman; D. Russell Wada; Britt-Marie Berling; Göran Benoni 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB

The aim of this study was to predict the disposition of midazolam in individual surgical patients by physiologically based pharmacokinetic (PBPK) modeling and explore the causes of interindividual variability. Tissue±plasma partition coef®cients (k p ) were scaled from rat to human values by a physi

A physiologically based pharmacokinetic
A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man
✍ Brett A. Howell; Anuj Chauhan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 893 KB

Physiologically based pharmacokinetic (PBPK) models were developed for design and optimization of liposome therapy for treatment of overdoses of tricyclic antidepressants and local anesthetics. In vitro drug-binding data for pegylated, anionic liposomes and published mechanistic equations for partit

Utility of a physiologically–based pharm
Utility of a physiologically–based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug–drug–disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice
✍ Joseph A. Grillo; Ping Zhao; Julie Bullock; Brian P. Booth; Min Lu; Kathy Robie- 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 535 KB

Background: Rivaroxaban is an oral Factor Xa inhibitor. The primary objective of this communication was to quantitatively predict changes in rivaroxaban exposure when individuals with varying degrees of renal impairment are co-administered with another drug that is both a P-gp and a moderate CYP3A4